Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Autologous Memory Lymphocyte（NewishT）for Hepatocellular Carcinoma With High Risk of Recurrence After Radical Resection

NCT05352646 is registered in ClinicalTrials.gov with Newish Technology (Beijing) Co., Ltd. as lead sponsor.

NCT NCT05352646
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05352646 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Autologous Memory Lymphocyte（NewishT）for Hepatocellular Carcinoma With High Risk of Recurrence After Radical Resection
Lead sponsor
Newish Technology (Beijing) Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
July 26, 2022
Completion date
December 31, 2024
Enrollment
26 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma